HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) is one of the worst performers on the stock market today. At current price of $0.55, the shares have already lost -0.01 points (-1.79% lower) from its previous close of $0.56. Should you buy or avoid them? The stock sets an active trading volume day with a reported 195374 contracts so far this session. HTGM shares had a relatively better volume day versus average trading capacity of 438.3 thousand shares, but with a 49.6 million float and a -3.45% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for HTGM stock indicates that the average analyst price target is $2.38 per share. This means the stock has a potential increase of 332.73% from where the HTGM share price has been trading recently.
During the recent trading session for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), the company witnessed their stock drop by $-0.02 over a week and tumble down $-0.12 from the price 20 days ago. When compared to their established 52-week high of $3.24, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 10/04/19. The recent low of $0.54 stood for a -83.02% since 02/13/20, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.59 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for HTG Molecular Diagnostics, Inc., the two-week RSI stands at 40.36. This figure suggests that HTGM stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current HTGM readings is similarly very revealing as it has a stochastic reading of 27.49% at this stage. This figure means that HTGM share price today is being overbought.
Technical chart claims that HTG Molecular Diagnostics, Inc. (HTGM) would settle between $0.59/share to $0.63/share level. However, if the stock price goes below the $0.53 mark, then the market for HTG Molecular Diagnostics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.51 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.01. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Rodman & Renshaw lifted target price for shares of HTGM but were stick to Buy recommendation for the stock in their opinion released on May 16. The price target has been raised from $4.50 to $6. Rodman & Renshaw, analysts launched coverage of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) stock with a Buy recommendation, according to their flash note issued to investors on August 22. Analysts at Canaccord Genuity are sticking to their Buy stance. However, on April 04, they lifted price target for these shares to $7 from $10.
HTGM equity has an average rating of 1.75, with the figure leaning towards a bullish end. 4 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 4 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 4 analysts rated HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, HTGM stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/E ratio is 0 while for the average stock in the same group, the multiple is 49.6. HTG Molecular Diagnostics, Inc. current P/B ratio of 1.2 means it is trading at a discount against its industry’s 5.
HTG Molecular Diagnostics, Inc. (HTGM)’s current-quarter revenues are projected to climb by nearly -37.2% to hit $4.85 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over -10.5% from $21.5 million to a noteworthy $19.25 million. At the other end of the current quarter income statement, HTG Molecular Diagnostics, Inc. is expected to see its adjusted earnings surge by roughly -28.6% to hit $-0.09 per share. For the fiscal year, HTGM’s earnings are projected to climb by roughly 8.3% to hit $-0.55 per share.